Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survivalLAMBA, R; ABELLA, E; KUKURUGA, D et al.Leukemia. 2004, Vol 18, Num 10, pp 1681-1686, issn 0887-6924, 6 p.Article

Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning : Reduced-intensity conditioning allogeneic stem cell transplantation: hype, reality or time for a rethink?BARON, F; SANDMAIER, B. M.Leukemia. 2006, Vol 20, Num 10, pp 1690-1700, issn 0887-6924, 11 p.Article

Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myelomaLUFT, Thomas; MOOS, Marion; GOLDSCHMIDT, Hartmut et al.British journal of haematology. 2003, Vol 123, Num 4, pp 646-653, issn 0007-1048, 8 p.Article

Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignanciesNAKAJIMA, H; OKI, M; MORI, S et al.Clinical and laboratory haematology. 2003, Vol 25, Num 6, pp 383-391, issn 0141-9854, 9 p.Article

Monitoring of donor chimerism in sorted CD34⁺ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantationBORNHÄUSER, Martin; OELSCHLAEGEL, Uta; THEUSER, Catrin et al.Haematologica (Roma). 2009, Vol 94, Num 11, pp 1613-1617, issn 0390-6078, 5 p.Article

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantationMEYER, R. G; WAGNER, E. M; KOLBE, K et al.Bone marrow transplantation (Basingstoke). 2010, Vol 45, Num 4, pp 668-674, issn 0268-3369, 7 p.Article

Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias : Acute leukemiasNIEDERWIESER, Dietger; GENTILINI, Chiara; HEGENBART, Ute et al.Critical reviews in oncology/hematology. 2005, Vol 56, Num 2, pp 275-281, issn 1040-8428, 7 p.Article

Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantationSOBECKS, R. M; BALL, E. J; DEAN, R et al.Bone marrow transplantation (Basingstoke). 2008, Vol 41, Num 8, pp 709-714, issn 0268-3369, 6 p.Article

Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiencySLATTER, M. A; BHATTACHARYA, A; ABINUN, M et al.Bone marrow transplantation (Basingstoke). 2005, Vol 35, Num 7, pp 683-689, issn 0268-3369, 7 p.Article

WT1-specific CTL cells of recipient origin may exist in the peripheral blood of patients achieving full donor chimerism soon after nonmyeloablative transplantationLI WEI; HONGLI ZUO; KAIXUN HU et al.Clinical transplantation. 2011, Vol 25, Num 5, pp 689-696, issn 0902-0063, 8 p.Article

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trialPLATZBECKER, U; WERMKE, M; MOHR, B et al.Leukemia. 2012, Vol 26, Num 3, pp 381-389, issn 0887-6924, 9 p.Article